ENDRA Life Sciences initiates review of strategic alternatives; board evaluates options including investments, mergers, and asset sales

Reuters03-25

ENDRA Life Sciences initiates review of strategic alternatives; board evaluates options including investments, mergers, and asset sales

The Board of Directors initiated a process to evaluate a range of strategic alternatives aimed at maximizing shareholder value.
Options under review include strategic investments, mergers, business combinations, in-licensing or collaboration arrangements, asset sales, or a sale or merger of the company.
Lucid Capital Management was engaged as financial advisor, and K&L Gates was engaged as legal counsel for the review process.
Chief Executive Officer Alexander Tokman said the review is intended to assess available options and determine the most appropriate path forward for the company and its shareholders.
Management plans to continue executing strategic and operating initiatives while the review is ongoing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ENDRA Life Sciences Inc. published the original content used to generate this news brief on March 25, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2622407316?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-25 20:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622407316","market":"us","top_or_hot":-1,"title":"ENDRA Life Sciences initiates review of strategic alternatives; board evaluates options including investments, mergers, and asset sales","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      ENDRA Life Sciences initiates review of strategic alternatives; board evaluates options including investments, mergers, and asset sales\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          The Board of Directors initiated a process to evaluate a range of strategic alternatives aimed at maximizing shareholder value.\n        </li>\n<li>\n          Options under review include strategic investments, mergers, business combinations, in-licensing or collaboration arrangements, asset sales, or a sale or merger of the company.\n        </li>\n<li>\n          <a href=\"https://laohu8.com/S/LCID\">Lucid</a> Capital Management was engaged as financial advisor, and <a href=\"https://laohu8.com/S/TKKD.SI\">K</a>&amp;L Gates was engaged as legal counsel for the review process.\n        </li>\n<li>\n          Chief Executive Officer Alexander Tokman said the review is intended to assess available options and determine the most appropriate path forward for the company and its shareholders.\n        </li>\n<li>\n          Management plans to continue executing strategic and operating initiatives while the review is ongoing.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/NDRA\">ENDRA Life Sciences Inc</a>. published the original content used to generate this news brief on March 25, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ENDRA Life Sciences initiates review of strategic alternatives; board evaluates options including investments, mergers, and asset sales</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nENDRA Life Sciences initiates review of strategic alternatives; board evaluates options including investments, mergers, and asset sales\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-25 20:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      ENDRA Life Sciences initiates review of strategic alternatives; board evaluates options including investments, mergers, and asset sales\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          The Board of Directors initiated a process to evaluate a range of strategic alternatives aimed at maximizing shareholder value.\n        </li>\n<li>\n          Options under review include strategic investments, mergers, business combinations, in-licensing or collaboration arrangements, asset sales, or a sale or merger of the company.\n        </li>\n<li>\n          <a href=\"https://laohu8.com/S/LCID\">Lucid</a> Capital Management was engaged as financial advisor, and <a href=\"https://laohu8.com/S/TKKD.SI\">K</a>&amp;L Gates was engaged as legal counsel for the review process.\n        </li>\n<li>\n          Chief Executive Officer Alexander Tokman said the review is intended to assess available options and determine the most appropriate path forward for the company and its shareholders.\n        </li>\n<li>\n          Management plans to continue executing strategic and operating initiatives while the review is ongoing.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/NDRA\">ENDRA Life Sciences Inc</a>. published the original content used to generate this news brief on March 25, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NDRA","symbol_name":"ENDRA Life Sciences Inc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nNDLZgyT1:1","article_id":"2622407316","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2622407316","pubTimestamp":1774440371,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"ENDRA Life Sciences initiates review of strategic alternatives; board evaluates options including investments, mergers, and asset sales. The Board of Directors initiated a process to evaluate a range of strategic alternatives aimed at maximizing shareholder value.Options under review include strategic investments, mergers, business combinations, in-licensing or collaboration arrangements, asset sales, or a sale or merger of the company.Lucid Capital Management was engaged as financial advisor, and K&L Gates was engaged as legal counsel for the review process.Chief Executive Officer Alexander Tokman said the review is intended to assess available options and determine the most appropriate path forward for the company and its shareholders.Management plans to continue executing strategic and operating initiatives while the review is ongoing.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and t","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NDRA":"ENDRA Life Sciences Inc","BK4082":"医疗保健设备"},"translate_title":"ENDRA Life Sciences启动战略替代方案审查；董事会评估包括投资、合并和资产出售在内的选择","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDRA":0.9},"content_text":"ENDRA Life Sciences initiates review of strategic alternatives; board evaluates options including investments, mergers, and asset sales\n    \n\n\n          The Board of Directors initiated a process to evaluate a range of strategic alternatives aimed at maximizing shareholder value.\n        \n\n          Options under review include strategic investments, mergers, business combinations, in-licensing or collaboration arrangements, asset sales, or a sale or merger of the company.\n        \n\nLucid Capital Management was engaged as financial advisor, and K&L Gates was engaged as legal counsel for the review process.\n        \n\n          Chief Executive Officer Alexander Tokman said the review is intended to assess available options and determine the most appropriate path forward for the company and its shareholders.\n        \n\n          Management plans to continue executing strategic and operating initiatives while the review is ongoing.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ENDRA Life Sciences Inc. published the original content used to generate this news brief on March 25, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"merge,event","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2622407316","isCrawlerRequest":true}